General anesthesia was induced in 60 patients with GH-secreting tumors (GH group, <i>n</i> = 30) or nonfunctioning pituitary tumors (NF group, <i>n</i> = 30) using an effect-site target-controlled intravenous propofol infusion.
We therefore analysed mortality in patients with only one underlying disorder, non-functioning pituitary adenoma (NFPA), with and without GH replacement therapy (GHRT).
The study population consisted of these nine patients with nonfunctioning pituitary adenoma (n = 5), mixed growth hormone and prolactin-secreting pituitary adenomas (n = 3), and a prolactinoma (n = 1).